, 39 patients ont eu une BP et une AUC à M12. Tous les patients étaient traités par tacrolimus

, Le délai moyen entre la transplantation et la réalisation de l'AUC était de 376±28 jours

L. , 8±15,2 h.mg/L. 28 % de patients avaient une AUC < 30 h.mg/L (Figure 2), 61,8 % une AUC entre 30 et 60 h.mg/L et 10,2 % avaient une AUC > 60 h.mg/L. Selon le site ABIS, la moitié des patients avaient une posologie adéquate de MMF pour un objectif, p.45

. Sept, Les 2 patients ont été traités par Solumedrol® 500 mg/j pendant 3 jours. Un patient avait une AUC > 30 h.mg/L et un, une AUC < 30 h

, Les 5 patients avaient une AUC > 30 h.mg/L. Ils n, -Cinq lésions borderline (quatre rejets : i1t2 et un rejet : i0t1)

, Deux BP montraient un marquage isolé du C4d au niveau des capillaires péritubulaires (dont une greffe ABO-incompatible). L'AUC était > 30 h.mg/L chez ces 2 patients

, Des lésions de FIAT étaient retrouvées chez 63 % des patients, dont l'AUC était < 30 h.mg/L et

%. , AUC était > 30 h.mg/L. Il y avait 64% d'inflammation dans les zones de fibrose dans le groupe AUC < 30 h.mg/L , contre 59% dans le groupe AUC > 30 h

, Des lésions vasculaires chroniques étaient retrouvées dans 70% des cas dans les 2 groupes

, Enfin, 4 (11%) BP (chez des patients dont la néphropathie initiale était indéterminée) montraient

M. Lassalle, E. Monnet, C. Ayav, J. Hogan, O. Moranne et al., Annual Report Digest of the Renal Epidemiology Information Network (REIN) registry, Transpl Int Off J Eur Soc Organ Transplant, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02931873

, Agence de la biomédecine -Le rapport annuel médical et scientifique 2017, 2019.

K. D. Yoo, C. T. Kim, M. Kim, J. Noh, G. Kim et al., Superior outcomes of kidney transplantation compared with dialysis. Medicine (Baltimore), vol.95, 2016.

, Qualité de vie des patients dialysés et transplantés rénaux : résultats de deux enquêtes multirégionales, 2019.

C. Legeai, R. M. Andrianasolo, O. Moranne, R. Snanoudj, M. Hourmant et al., Benefits of kidney transplantation for a national cohort of patients aged 70 years and older starting renal replacement therapy, Am J Transplant, vol.18, issue.11, pp.2695-707, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02359418

J. M. Morales, R. Marcén, D. Del-castillo, A. Andres, M. Gonzalez-molina et al., Risk factors for graft loss and mortality after renal transplantation according to recipient age: a prospective multicentre study, Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc -Eur Ren Assoc, vol.27, issue.4, pp.39-46, 2012.

J. Sellarés, D. G. Freitas, . De, M. Mengel, J. Reeve et al., Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody-Mediated Rejection and Nonadherence, Am J Transplant, vol.12, issue.2, pp.388-99, 2012.

U. Yakupoglu, E. Baranowska-daca, D. Rosen, R. Barrios, W. N. Suki et al., Post-transplant nephrotic syndrome: A comprehensive clinicopathologic study, Kidney Int, vol.65, issue.6, pp.2360-70, 2004.

A. P. Monaco, J. F. Burke, R. M. Ferguson, P. F. Halloran, B. D. Kahan et al., Current thinking on chronic renal allograft rejection: issues, concerns, and recommendations from a 1997 roundtable discussion, Am J Kidney Dis Off J Natl Kidney Found, vol.33, issue.1, pp.150-60, 1999.

B. J. Nankivell, R. J. Borrows, C. Fung, O. Connell, P. J. Allen et al., The natural history of chronic allograft nephropathy, N Engl J Med, vol.349, issue.24, pp.2326-2359, 2003.

S. Mohan, A. Palanisamy, D. Tsapepas, B. Tanriover, R. J. Crew et al., Donor-Specific Antibodies Adversely Affect Kidney Allograft Outcomes, J Am Soc Nephrol JASN, vol.23, issue.12, pp.2061-71, 2012.

P. S. Rao and A. Ojo, The alphabet soup of kidney transplantation: SCD, DCD, ECD--fundamentals for the practicing nephrologist, Clin J Am Soc Nephrol CJASN, vol.4, issue.11, pp.1827-1858, 2009.

D. A. Shoskes and P. F. Halloran, Delayed graft function in renal transplantation: etiology, management and long-term significance, J Urol, vol.155, issue.6, pp.1831-1871, 1996.

A. O. Ojo, R. A. Wolfe, P. J. Held, F. K. Port, and R. L. Schmouder, Delayed graft function: risk factors and implications for renal allograft survival, Transplantation, vol.63, issue.7, pp.968-74, 1997.

B. J. Nankivell and D. Kuypers, Diagnosis and prevention of chronic kidney allograft loss, Lancet Lond Engl, vol.378, issue.9800, pp.1428-1465, 2011.

C. Wiebe, I. W. Gibson, T. D. Blydt-hansen, M. Karpinski, J. Ho et al., Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.12, issue.5, pp.1157-67, 2012.

J. A. Butler, P. Roderick, M. Mullee, J. C. Mason, and R. C. Peveler, Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review, Transplantation, vol.77, issue.5, pp.769-76, 2004.

T. E. Nevins, P. W. Nickerson, and M. A. Dew, Understanding Medication Nonadherence after Kidney Transplant, J Am Soc Nephrol JASN, vol.28, issue.8, pp.2290-301, 2017.

C. Roufosse, N. Simmonds, M. Clahsen-van-groningen, M. Haas, K. J. Henriksen et al., Reference Guide to the Banff Classification of Renal Allograft Pathology, Transplantation, vol.102, issue.11, p.1795, 2018.

F. V. Veronese, R. C. Manfro, F. R. Roman, M. I. Edelweiss, D. N. Rush et al., Reproducibility of the Banff classification in subclinical kidney transplant rejection, Clin Transplant, vol.19, issue.4, pp.518-539, 2005.

M. Haas, The relationship between pathologic lesions of active and chronic antibody-mediated rejection in renal allografts, Am J Transplant, vol.18, issue.12, pp.2849-56, 2018.

B. J. Nankivell, N. Agrawal, A. Sharma, A. Taverniti, P. Ng et al., The clinical and pathological significance of borderline T cell-mediated rejection, Am J Transplant, vol.19, issue.5, pp.1452-63, 2019.

D. Rush, P. Nickerson, J. Gough, R. Mckenna, P. Grimm et al., Beneficial effects of treatment of early subclinical rejection: a randomized study, J Am Soc Nephrol JASN, vol.9, issue.11, pp.2129-2163, 1998.

B. S. Choi, M. J. Shin, S. J. Shin, Y. S. Kim, Y. J. Choi et al., Clinical Significance of an Early Protocol Biopsy in Living-Donor Renal Transplantation: Ten-Year Experience at a Single Center, Am J Transplant, vol.5, issue.6, pp.1354-60, 2005.

M. Mengel, J. R. Chapman, F. G. Cosio, M. W. Cavaillé-coll, H. Haller et al., Protocol biopsies in renal transplantation: insights into patient management and pathogenesis, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.7, issue.3, pp.512-519, 2007.

C. Legendre, E. Thervet, H. Skhiri, M. F. Mamzer-bruneel, F. Cantarovich et al., Histologic features of chronic allograft nephropathy revealed by protocol biopsies in kidney transplant recipients, Transplantation, vol.65, issue.11, pp.1506-1515, 1998.

J. Beimler and M. Zeier, Borderline rejection after renal transplantation--to treat or not to treat, Clin Transplant, vol.23, pp.19-25, 2009.

A. Wilkinson, Protocol transplant biopsies: are they really needed?, Clin J Am Soc Nephrol CJASN, vol.1, issue.1, pp.130-137, 2006.

J. M. Gloor, A. J. Cohen, D. J. Lager, J. P. Grande, M. E. Fidler et al., Subclinical rejection in tacrolimus-treated renal transplant recipients, Transplantation, vol.73, issue.12, pp.1965-1973, 2002.

D. Serón, F. Moreso, J. Bover, E. Condom, S. Gil-vernet et al., Early protocol renal allograft biopsies and graft outcome, Kidney Int, vol.51, issue.1, pp.310-316, 1997.

T. Kee, J. R. Chapman, P. J. O&apos;connell, C. Fung, R. Allen et al., Treatment of subclinical rejection diagnosed by protocol biopsy of kidney transplants, Transplantation, vol.82, issue.1, pp.36-42, 2006.

I. Roberts, S. Reddy, C. Russell, D. R. Davies, P. J. Friend et al., Subclinical rejection and borderline changes in early protocol biopsy specimens after renal transplantation, Transplantation, vol.77, issue.8, pp.1194-1202, 2004.

A. Loupy, C. Suberbielle-boissel, G. S. Hill, C. Lefaucheur, D. Anglicheau et al., Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donorspecific antibodies, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.9, issue.11, pp.2561-70, 2009.

M. Haas, R. A. Montgomery, D. L. Segev, M. H. Rahman, L. C. Racusen et al., Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.7, issue.3, pp.576-85, 2007.

B. J. Nankivell, M. Shingde, K. L. Keung, C. Fung, R. J. Borrows et al., The causes, significance and consequences of inflammatory fibrosis in kidney transplantation: The Banff i-IFTA lesion, Am J Transplant, vol.18, issue.2, pp.364-76, 2018.

R. R. Redfield, K. R. Mccune, A. Rao, E. Sadowski, M. Hanson et al., Nature, timing, and severity of complications from ultrasound-guided percutaneous renal transplant biopsy, Transpl Int, vol.29, issue.2, pp.167-72, 2016.

A. Schwarz, W. Gwinner, M. Hiss, J. Radermacher, M. Mengel et al., Safety and adequacy of renal transplant protocol biopsies, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.5, issue.8, pp.1992-1998, 2005.

P. Dalal, G. Shah, D. Chhabra, and L. Gallon, Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients, Int J Nephrol Renov Dis, vol.3, pp.107-122, 2010.

A. Hart, J. M. Smith, M. A. Skeans, S. K. Gustafson, D. E. Stewart et al., Annual Data Report: Kidney, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.17, issue.1, pp.21-116, 2015.

H. Meier-kriesche, J. D. Schold, T. R. Srinivas, R. J. Howard, S. Fujita et al., Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.5, issue.9, pp.2273-80, 2005.

E. Group, Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. The Lancet, vol.345, pp.1321-1326, 1995.

G. Opelz and B. Döhler, Collaborative Transplant Study. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation, Transplantation, vol.87, issue.6, pp.795-802, 2009.

H. W. Sollinger, Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group, Transplantation, vol.60, issue.3, pp.225-257, 1995.

, A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group, Transplantation, vol.61, issue.7, pp.1029-1066, 1996.

P. F. Halloran, Immunosuppressive Drugs for Kidney Transplantation, N Engl J Med, vol.351, issue.26, pp.2715-2744, 2004.

H. W. Florey, M. A. Jennings, K. Gilliver, and A. G. Sanders, Mycophenolic acid an antibiotic from penicillum brevicompactum dierckx. The Lancet, vol.247, pp.46-55, 1946.

R. E. Bullingham, A. J. Nicholls, and B. R. Kamm, Clinical pharmacokinetics of mycophenolate mofetil, Clin Pharmacokinet, vol.34, issue.6, pp.429-55, 1998.

P. Halloran, T. Mathew, S. Tomlanovich, C. Groth, L. Hooftman et al., Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups, Transplantation, vol.63, issue.1, pp.39-47, 1997.

M. González-molina, D. Burgos, M. Cabello, P. Ruiz-esteban, M. A. Rodríguez et al., Impact of immunosuppression treatment on the improvement in graft survival after deceased donor renal transplantation: a long-term cohort study, Nefrol Engl Ed, vol.34, issue.5, pp.570-578, 2014.

J. J. Lipsky, Mycophenolate mofetil. The Lancet, vol.348, pp.1357-1366, 1996.

, Base purique pyrimidique purine nucleotide Enseignement recherche biochimie enzymologie bioinformatique Emmanuel Jaspard Universite Angers biochimej, 2019.

C. E. Staatz and S. E. Tett, Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update, Arch Toxicol, vol.88, issue.7, pp.1351-89, 2014.

A. Djamali, A. Vidyasagar, G. Yagci, L. Huang, and S. Reese, Mycophenolic acid may delay allograft fibrosis by inhibiting TGF-?1-induced activation of Nox-2 via the NF-?B pathway, Transplantation, vol.90, issue.4, pp.387-93, 2010.

M. P. Dell&apos;oglio, G. Zaza, M. Rossini, C. Divella, P. Pontrelli et al., The Anti-Fibrotic Effect of Mycophenolic Acid-Induced Neutral Endopeptidase, J Am Soc Nephrol JASN, vol.21, issue.12, pp.2157-68, 2010.

H. Ekberg, H. Tedesco-silva, A. Demirbas, S. Vítko, B. Nashan et al., Reduced exposure to calcineurin inhibitors in renal transplantation, N Engl J Med, vol.357, issue.25, pp.2562-75, 2007.

B. J. Nankivell, M. D. Wavamunno, R. J. Borrows, M. Vitalone, C. Fung et al., Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.7, issue.2, pp.366-76, 2007.

K. Mihovilovi?, B. Maksimovi?, B. Kocman, D. Gu?tin, ?. Vidas et al., Effect of mycophenolate mofetil on progression of interstitial fibrosis and tubular atrophy after kidney transplantation: a retrospective study, BMJ Open, vol.4, issue.7, p.5005, 2014.

M. Naesens, H. De-loor, Y. Vanrenterghem, and D. Kuypers, The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. Transplantation, vol.84, pp.362-73, 2007.

P. Ferreira, F. V. Thiesen, T. T. De-araujo, D. &apos;ávila, D. O. Gadonski et al., Comparison of plasma and oral fluid concentrations of mycophenolic acid and its glucuronide metabolite by LC-MS in kidney transplant patients, Eur J Clin Pharmacol, vol.75, issue.4, pp.553-562, 2019.

M. Shipkova, V. W. Armstrong, L. Weber, P. D. Niedmann, E. Wieland et al., Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients, Ther Drug Monit, vol.24, issue.3, pp.390-399, 2002.

S. Kofler, N. Shvets, A. K. Bigdeli, M. A. König, P. Kaczmarek et al., Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.9, issue.7, pp.1650-1656, 2009.

K. S. Patel, B. R. Stephany, J. F. Barnes, S. R. Bauer, and M. L. Spinner, Renal Transplant Acute Rejection with Lower Mycophenolate Mofetil Dosing and Proton Pump Inhibitors or Histamine-2 Receptor Antagonists, Pharmacother J Hum Pharmacol Drug Ther, vol.37, issue.12, pp.1507-1522, 2017.

P. Marquet, E. Billaud, and F. Saint-marcoux, Suivi thérapeutique pharmacologique de l'acide mycophénolique. Wwwem-Premiumcomdatatraitesbioemb-75443, 2018.

S. Bunnapradist and P. M. Ambühl, Impact of gastrointestinal-related side effects on mycophenolate mofetil dosing and potential therapeutic strategies, Clin Transplant, vol.22, issue.6, pp.815-836, 2008.

N. M. Davies, J. Grinyó, R. Heading, B. Maes, H. Meier-kriesche et al., Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal, Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc -Eur Ren Assoc, vol.22, issue.9, pp.2440-2448, 2007.

M. M. Tielemans, G. Van-boekel, T. Van-gelder, E. T. Tjwa, and L. B. Hilbrands, Immunosuppressive drugs and the gastrointestinal tract in renal transplant patients, Transplant Rev Orlando Fla, vol.33, issue.2, pp.55-63, 2019.

T. Gelder, L. B. Hilbrands, Y. Vanrenterghem, W. Weimar, J. W. De-fijter et al., A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation, Transplantation, vol.68, issue.2, pp.261-267, 1999.

T. Van-gelder and D. A. Hesselink, Mycophenolate revisited, Transpl Int Off J Eur Soc Organ Transplant, vol.28, issue.5, pp.508-523, 2015.

T. Definitions-of and . &amp;ct, , 2019.

C. Seger, M. Shipkova, U. Christians, E. M. Billaud, P. Wang et al., Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice: Recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee, Ther Drug Monit, vol.38, issue.2, pp.170-89, 2016.

M. Brunet, T. Van-gelder, A. Åsberg, V. Haufroid, D. A. Hesselink et al., Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report, Ther Drug Monit, vol.41, issue.3, p.261, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02150345

A. Prémaud, A. Rousseau, N. Picard, and P. Marquet, Determination of mycophenolic acid plasma levels in renal transplant recipients co-administered sirolimus: comparison of an enzyme multiplied immunoassay technique (EMIT) and liquid chromatography-tandem mass spectrometry, Ther Drug Monit, vol.28, issue.2, pp.274-281, 2006.

D. Kuypers, Y. L. Meur, M. Cantarovich, M. J. Tredger, S. E. Tett et al., Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation, Clin J Am Soc Nephrol, vol.5, issue.2, pp.341-58, 2010.

L. Guellec, C. Bourgoin, H. Büchler, M. , L. Meur et al., Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients, Clin Pharmacokinet, vol.43, issue.4, pp.253-66, 2004.

A. Prémaud, J. Debord, A. Rousseau, L. Meur, Y. Toupance et al., A double absorptionphase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil, Clin Pharmacokinet, vol.44, issue.8, pp.837-884, 2005.

F. Saint-marcoux, S. Vandierdonck, A. Prémaud, J. Debord, A. Rousseau et al., Large scale analysis of routine dose adjustments of mycophenolate mofetil based on global exposure in renal transplant patients, Ther Drug Monit, vol.33, issue.3, pp.285-94, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00590457

T. Van-gelder, H. T. Silva, J. W. De-fijter, K. Budde, D. Kuypers et al., Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial: Transplantation, vol.86, pp.1043-51, 2008.

S. Gourishankar, I. Houde, P. A. Keown, D. Landsberg, C. J. Cardella et al., The CLEAR Study: A 5-day, 3-g Loading Dose of Mycophenolate Mofetil versus Standard 2-g Dosing in Renal Transplantation, Clin J Am Soc Nephrol CJASN, vol.5, issue.7, pp.1282-1291, 2010.

M. D. Hale, A. J. Nicholls, R. E. Bullingham, R. Hené, A. Hoitsma et al., The pharmacokineticpharmacodynamic relationship for mycophenolate mofetil in renal transplantation, Clin Pharmacol Ther, vol.64, issue.6, pp.672-83, 1998.

B. Kulabusaya, S. Vadcharavivad, Y. Avihingsanon, T. Van-gelder, and K. Praditpornsilpa, Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients, Int J Clin Pharm, vol.41, issue.4, pp.1047-55, 2019.

L. Meur, Y. Büchler, M. Thierry, A. Caillard, S. Villemain et al., Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation, Am J Transplant, vol.7, issue.11, pp.2496-503, 2007.

R. S. Gaston, B. Kaplan, T. Shah, D. Cibrik, L. M. Shaw et al., Fixed-or Controlled-Dose Mycophenolate Mofetil with Standard-or Reduced-Dose Calcineurin Inhibitors: The Opticept Trial, Am J Transplant, vol.9, issue.7, pp.1607-1626, 2009.

L. Meur, Y. Thierry, A. Glowacki, F. Rerolle, J. Garrigue et al., Early steroid withdrawal and optimization of mycophenolic acid exposure in kidney transplant recipients receiving mycophenolate mofetil, Transplantation, vol.92, issue.11, pp.1244-51, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01151208

D. Rizopoulos, L. Meur, Y. Prémaud, A. Woillard, J. B. Rérolle et al., Impact of longitudinal exposure to mycophenolic acid on acute rejection in renal-transplant recipients using a joint modeling approach, Pharmacol Res, vol.72, pp.52-60, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00809389

Z. Daher-abdi, A. Prémaud, M. Essig, A. S. Munteanu, E. Garnier et al., Exposure to mycophenolic acid better predicts immunosuppressive efficacy than exposure to calcineurin inhibitors in renal transplant patients, Clin Pharmacol Ther, vol.96, issue.4, pp.508-523, 2014.

B. A. Kiberd, J. Lawen, and C. Daley, Limits to Intensified Mycophenolate Mofetil Dosing in Kidney Transplantation: Ther Drug Monit, vol.34, pp.736-744, 2012.

M. Hazzan, M. Labalette, M. C. Copin, F. Glowacki, F. Provôt et al., Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial, J Am Soc Nephrol JASN, vol.16, issue.8, pp.2509-2525, 2005.

C. Ding, L. Jiao, F. Han, H. Xiang, P. Tian et al., Early Immunosuppressive Exposure of Enteric-Coated-Mycophenolate Sodium Plus Tacrolimus Associated with Acute Rejection in Expanded Criteria Donor Kidney Transplantation, Chin Med J (Engl), vol.131, issue.11, pp.1302-1309, 2018.

T. Gelder, L. Meur, Y. Shaw, L. M. Oellerich, M. Denofrio et al., Therapeutic drug monitoring of mycophenolate mofetil in transplantation, Ther Drug Monit, vol.28, issue.2, pp.145-54, 2006.

A. M. Strommen, M. C. Moss, J. Goebel, and M. Bock, Donor-specific antibodies in a pediatric kidney transplant population-Prevalence and association with antiproliferative drug dosing, Pediatr Transplant, vol.0, issue.0, p.13511

C. M. Cruz, S. Pereira, J. Gandara, S. Ferreira, V. Lopes et al., Efficacy and Safety of Monotherapy With Mycophenolate Mofetil in Liver Transplantation Patients With Nephrotoxicity, Transplant Proc, vol.48, issue.7, pp.2341-2344, 2016.

H. Chen and B. Chen, Clinical mycophenolic acid monitoring in liver transplant recipients, World J Gastroenterol WJG, vol.20, issue.31, pp.10715-10743, 2014.

C. C. Mok, Mycophenolate mofetil for lupus nephritis: an update, Expert Rev Clin Immunol, vol.11, issue.12, pp.1353-64, 2015.

N. Zahr, L. Arnaud, P. Marquet, J. Haroche, N. Costedoat-chalumeau et al., Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil, Arthritis Rheum, vol.62, issue.7, pp.2047-54, 2010.

B. J. Nankivell and J. R. Chapman, The Significance of Subclinical Rejection and the Value of Protocol Biopsies, Am J Transplant, vol.6, issue.9, pp.2006-2018, 2006.

T. Kiang and M. Ensom, Exposure-Toxicity Relationships of Mycophenolic Acid in Adult Kidney Transplant Patients, Clin Pharmacokinet, 2019.

A. O. Ojo, H. U. Meier-kriesche, J. A. Hanson, A. B. Leichtman, D. Cibrik et al., Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection, Transplantation, vol.69, issue.11, pp.2405-2414, 2000.

M. J. Everly, L. M. Rebellato, C. E. Haisch, M. Ozawa, K. Parker et al., Incidence and impact of de novo donor-specific alloantibody in primary renal allografts, Transplantation, vol.95, issue.3, pp.410-417, 2013.

B. Degirmenci, R. Albayrak, A. Haktanir, M. Acar, and A. Yucel, Acute effect of smoking on gallbladder emptying and refilling in chronic smokers and nonsmokers: a sonographic study, World J Gastroenterol, vol.12, issue.34, pp.5540-5543, 2006.

M. Okour, P. A. Jacobson, M. A. Ahmed, A. K. Israni, and R. C. Brundage, Mycophenolic acid (MPA) and its metabolites in kidney transplant recipients: a semi-mechanistic enterohepatic circulation model to improve estimating exposure, J Clin Pharmacol, vol.58, issue.5, pp.628-667, 2018.

H. L. Cilião, R. Camargo-godoy, M. F. Souza, . De, A. Zanuto et al., Cólus IM de S. Polymorphisms in IMPDH2, UGT2B7, and CES2 genes influence the risk of graft rejection in kidney transplant recipients taking mycophenolate mofetil, Mutat Res Toxicol Environ Mutagen, vol.836, pp.97-102, 2018.

A. E. Mendonza, R. Y. Gohh, and F. Akhlaghi, Analysis of mycophenolic acid in saliva using liquid chromatography tandem mass spectrometry, Ther Drug Monit, vol.28, issue.3, pp.402-408, 2006.